RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) and GlycoMimetics (NASDAQ:GLYC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.

Profitability

This table compares RegeneRx Biopharmaceuticals and GlycoMimetics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
RegeneRx Biopharmaceuticals -752.96% N/A -113.34%
GlycoMimetics N/A -24.09% -23.11%

Earnings & Valuation

This table compares RegeneRx Biopharmaceuticals and GlycoMimetics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
RegeneRx Biopharmaceuticals $70,000.00 319.38 -$1.99 million N/A N/A
GlycoMimetics $20,000.00 26,750.63 -$48.27 million ($1.18) -10.50

RegeneRx Biopharmaceuticals has higher revenue and earnings than GlycoMimetics.

Institutional and Insider Ownership

0.1% of RegeneRx Biopharmaceuticals shares are owned by institutional investors. 10.9% of RegeneRx Biopharmaceuticals shares are owned by insiders. Comparatively, 26.8% of GlycoMimetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

RegeneRx Biopharmaceuticals has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, GlycoMimetics has a beta of 2.47, indicating that its stock price is 147% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for RegeneRx Biopharmaceuticals and GlycoMimetics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RegeneRx Biopharmaceuticals 0 0 0 0 N/A
GlycoMimetics 0 0 5 0 3.00

GlycoMimetics has a consensus price target of $25.50, suggesting a potential upside of 105.81%. Given GlycoMimetics’ higher probable upside, analysts clearly believe GlycoMimetics is more favorable than RegeneRx Biopharmaceuticals.

Summary

GlycoMimetics beats RegeneRx Biopharmaceuticals on 7 of the 11 factors compared between the two stocks.

About RegeneRx Biopharmaceuticals

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4 (Tß4), for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It also evaluates the commercial development of peptide fragments and derivatives of Tß4 for potential cosmeceutical and other personal care uses. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was founded in 1982 and is headquartered in Rockville, Maryland.

About GlycoMimetics

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc. It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML. In addition, the company offers GMI-1359 that has completed Phase I clinical trial to target E-selectin and a chemokine receptor for various tumor types. Further, it is developing various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.

Receive News & Ratings for RegeneRx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RegeneRx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.